ClinicalTrials.gg

Program

CM336

A development code. Also written as “CM336 Injection”, “CM336 Injection(Low dose group)” and “CM336 Injection(High dose group)”.

Its studies are mostly in Multiple Myeloma · Purpura, Thrombocytopenic, Idiopathic · Amyloidosis, led by Keymed Biosciences.

Furthest: phase 3, since Sep 12, 20255 company-led studies, 5 open or runningNext primary completion: Sep 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Keymed Biosciences55 open or runningphase 3since Sep 12, 2025Jun 18, 2025Sep 2027phase 3 · NCT07181239

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 18, 2025First study: phase 2 study in Primary Light-Chain AmyloidosisFirst studyNCT07039578 · 90 planned · China
  2. Aug 29, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07175493 · 158 planned · China
  3. Sep 12, 2025Phase 3 study in Multiple MyelomaNCT07181239 · 280 planned · China
  4. Jun 8, 2026Phase 1 study in Primary Sjögren's Syndrome (pSS)NCT07642843 · 30 planned · China
  5. Oct 27, 2026Phase 3 study in Multiple MyelomaNCT07910903 · 320 planned · China

Ahead

  1. Sep 2027Primary completion: phase 3 study in Multiple MyelomaNCT07181239
  2. Nov 18, 2027Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07175493
  3. Apr 2028Primary completion: phase 1 study in Primary Sjögren's Syndrome (pSS)NCT07642843
  4. May 2030Primary completion: phase 3 study in Multiple MyelomaNCT07910903

TargetBeta

CD3E →read by rule
“The goal of this clinical trial is to evaluate whether CM336, a BCMA/CD3 bispecific antibody, in combination with daratumumab and lenalidomide can induce deep and durable responses in adults with transplant-ineligible newly diagnosed multiple myeloma (NDMM).”study text, by rule · the study

Other programs on CD3E

ProgramCompanyFurthest phaseStudies
etentamigAbbViephase 311
obrixtamigBoehringer Ingelheimphase 311
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
cevostamabHoffmann-La Rochephase 38
ramantamigJohnson & Johnsonphase 37
pasritamigJohnson & Johnsonphase 35
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
gocatamigMerckphase 34
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07910903Multiple Myeloma · China3Not yet recruitingMay 2030320
NCT07642843Primary Sjögren's Syndrome (pSS) · China1Not yet recruitingApr 202830
NCT07181239Multiple Myeloma · China3Not yet recruitingSep 2027280
NCT07175493Purpura, Thrombocytopenic, Idiopathic · China2RecruitingNov 18, 2027158
NCT07039578Primary Light-Chain Amyloidosis · China2RecruitingJun 30, 202690

How it is read

Names in the registry

  • “CM336”, 2 entries
  • “CM336 Injection”, 2 entries
  • “CM336 Injection(Low dose group)”, 1 entry
  • “CM336 Injection(High dose group)”, 1 entry

Codes read as this program: CM336.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.